Predict your next investment

Venture Capital
FINANCE
rctech.com

See what CB Insights has to offer

Investments

53

Portfolio Exits

3

Funds

3

Partners & Customers

8

About Research Corporation Technologies

Research Corporation Technologies in Tucson, Ariz., is a technology investment and management company that provides early-stage funding and development for promising biomedical companies and technologies. RCT focuses on technology investments with origins from universities and research institutions worldwide.Founded in 1987, the company carries on a vision chartered in 1912 by Frederick Gardner Cottrell, a university professor and inventor who championed the transfer of academic innovation to commercial use. RCT has assets of more than $200 million to advance technology development through venture investment, partnerships and special licensing programs.To support these programs, RCT has staff in its corporate office in Tucson, Ariz., and on the Atlantic and Pacific Coasts. RCT also has an affiliate company in the United Kingdom, Cambridge Research Biolventures (CRB), and an alliance with Start-Up Australia in Sydney.Research Corporation Technologies RCT BioVentures program provides venture capital to companies whose technologies have the potential to become significant biomedical products. Their current investment interests include novel therapeutics, devices and medical technology platforms.

Research Corporation Technologies Headquarter Location

5210 East Williams Circle Suite 240

Tucson, Arizona, 85711,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Research Corporation Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Research Corporation Technologies in 1 Expert Collection, including Advanced Materials.

A

Advanced Materials

1,253 items

Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.

Research Corporation Technologies Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Research Corporation Technologies Rank

Latest Research Corporation Technologies News

C-Path Launches Unique Translational Therapeutics Accelerator With Support From Cottrell Foundation

Jun 10, 2022

The global accelerator will transform academic discoveries to drug development opportunities Tucson, AZ /PRNewswire/ - Critical Path Institute (C-Path) today announced it has been awarded a grant from the Frederick Gardner Cottrell Foundation , a non-profit organization established by Research Corporation Technologies, Inc. (RCT) that provides financial support for scientific research and educational programs, to create the C-Path Translational Therapeutics Accelerator (TRxA). The accelerator is a unique, global effort focused on supporting academic scientists in defining optimal strategies for advancing new, cutting-edge therapeutics from the lab to patients. Advancing an idea from academic drug discovery research to human clinical trials is time and resource intensive, and, too frequently, unsuccessful. This transition from preclinical to clinical studies is therefore often referred to as the drug development 'valley of death.' Many aspects contribute to this valley of death, but key opportunities exist for TRxA to have a positive impact to bridge this gap. One such opportunity is to leverage C-Path's proficiencies in translational and regulatory science. In keeping with C-Path's role as a unique, neutral convener between academia, industry, regulatory agencies and patients, TRxA will provide university-based researchers with advice to define optimal regulatory strategies to advance promising new drug candidates. Additionally, TRxA will have funding available to complete critical studies needed to validate the solidity of the drug product for further development. By harnessing C-Path's expertise in accelerating the medical product development process, grant awardees will receive guidance and mentoring to enhance the efficiency and effectiveness of advancing potential therapies from early discovery to clinical trials — starting with a clear end in mind. Leading TRxA is newly hired Executive Director Maaike Everts, Ph.D., a pharmaceutical scientist with broad experience in drug delivery, discovery and development. Everts previously led a drug discovery program at the University of Alabama at Birmingham, and also has expertise in a CDMO environment for drug formulation and manufacturing. She will apply her firsthand experience to provide pivotal leadership, as TRxA begins accepting applications and issuing awards. "I am honored and excited to have the opportunity to shepherd TRxA through its growth into a world-class drug accelerator program," said Everts. "Helping academic researchers move their innovative ideas for new drugs from concept to reality is a personal passion, and a multidisciplinary team approach is critical to bringing new therapies to patients as quickly as possible." "C-Path is exceptionally well-suited to offer a novel translational accelerator program that will support a comprehensive strategic approach for academic groups facing the valley of death," explained Klaus Romero, M.D., M.S., F.C.P., C-Path's Chief Science Officer and Executive Director of Clinical Pharmacology. "In this accelerator model, C-Path will leverage our core competencies to provide strategic and tactical regulatory science guidance, engage relevant stakeholders when needed and bring diverse expertise to pivotal early-stage study design and implementation." "Our Cottrell Foundation has been a supporter of C-Path from its inception, and we have watched it develop into a world-class organization that catalyzes the development process of new medicines working with the FDA, EMA, industry, academia and patients. TRxA represents a unique opportunity to harness the strengths of C-Path to optimize the advancement of new therapies originating at universities and research institutions worldwide, and we're proud to partner with C-Path on this innovative venture," said Shaun Kirkpatrick, President, Biotechnologies, at RCT. "TRxA will provide resources and expertise to support academic scientists in developing a robust research plan and validating comprehensive data packages for potential drug candidates, a key to garnering interest from biotechnology and pharmaceutical companies who would further work with the academic scientist to bring promising drug candidates to the health care setting." To learn more about TRxA, be informed when the award application period opens and how to apply for an award, visit c-path.org/programs/trxa or contact C-Path at TRxA@c-path.org . About C-Path Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and hundreds of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona, C-Path in Europe is headquartered in Amsterdam, Netherlands and C-Path Ltd. operates from Dublin, Ireland with additional staff in multiple other locations. For more information, visit c-path.org .

Research Corporation Technologies Investments

53 Investments

Research Corporation Technologies has made 53 investments. Their latest investment was in Biolog as part of their Unattributed VC on May 5, 2022.

CBI Logo

Research Corporation Technologies Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/12/2022

Unattributed VC

Biolog

Yes

1

4/4/2022

Series D

Q'Apel Medical

$29.9M

No

2

3/31/2022

Series C

seqWell

$7M

No

3

2/12/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

10/16/2020

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/12/2022

4/4/2022

3/31/2022

2/12/2021

10/16/2020

Round

Unattributed VC

Series D

Series C

Series C

Unattributed VC

Company

Biolog

Q'Apel Medical

seqWell

Subscribe to see more

Subscribe to see more

Amount

$29.9M

$7M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

2

3

10

10

Research Corporation Technologies Portfolio Exits

3 Portfolio Exits

Research Corporation Technologies has 3 portfolio exits. Their latest portfolio exit was Catalyst Biosciences on March 05, 2015.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/5/2015

Merger

$99M

1

10/15/2013

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

1/24/2011

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

Date

3/5/2015

10/15/2013

1/24/2011

Exit

Merger

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

10

0

Research Corporation Technologies Acquisitions

1 Acquisition

Research Corporation Technologies acquired 1 company. Their latest acquisition was Translational Drug Development on June 04, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/4/2020

$99M

Acquired

3

Date

6/4/2020

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acquired

Sources

3

Research Corporation Technologies Fund History

3 Fund Histories

Research Corporation Technologies has 3 funds, including BioVentures Australia.

Closing Date

Fund

Fund Type

Status

Amount

Sources

BioVentures Australia

UNKNOWN

Unknown

1

Cambridge Research BioVentures

Subscribe to see more

Subscribe to see more

10

RCT BioVentures

Subscribe to see more

Subscribe to see more

10

Closing Date

Fund

BioVentures Australia

Cambridge Research BioVentures

RCT BioVentures

Fund Type

UNKNOWN

Subscribe to see more

Subscribe to see more

Status

Unknown

Subscribe to see more

Subscribe to see more

Amount

Sources

1

10

10

Research Corporation Technologies Partners & Customers

8 Partners and customers

Research Corporation Technologies has 8 strategic partners and customers. Research Corporation Technologies recently partnered with VTU Technology on December 12, 2014.

Date

Type

Business Partner

Country

News Snippet

Sources

12/3/2014

Partner

Austria

Tucson, Arizona and Grambach, Austria – Dec 03, 2014. Research Corporation TechnologiesResearch Corporation Technologies. RCT and VTU Technology Partner to Offer Custom Glycoprotein Production in Pichia GlycoSwitch.

`` We are delighted to offer Pichia GlycoSwitch ® engineered with our broad portfolio of Pichia tools in this partnership with VTU Technology and I am convinced that our yield enhancing technologies will give GlycoSwitch ® an exciting extra edge for the production of glycoproteins with Man5 -- or other human-like glycoforms '' , states Thomas Purkarthofer , Ph.D. , Head of Business Development of VTU Technology .

1

12/3/2014

Partner

Austria

Subscribe to see more

Subscribe to see more

10

6/4/2013

Partner

United States

Subscribe to see more

Subscribe to see more

10

7/11/2012

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

6/25/2009

Licensor

United States

Subscribe to see more

Subscribe to see more

10

Date

12/3/2014

12/3/2014

6/4/2013

7/11/2012

6/25/2009

Type

Partner

Partner

Partner

Partner

Licensor

Business Partner

Country

Austria

Austria

United States

United Kingdom

United States

News Snippet

Tucson, Arizona and Grambach, Austria – Dec 03, 2014. Research Corporation TechnologiesResearch Corporation Technologies. RCT and VTU Technology Partner to Offer Custom Glycoprotein Production in Pichia GlycoSwitch.

`` We are delighted to offer Pichia GlycoSwitch ® engineered with our broad portfolio of Pichia tools in this partnership with VTU Technology and I am convinced that our yield enhancing technologies will give GlycoSwitch ® an exciting extra edge for the production of glycoproteins with Man5 -- or other human-like glycoforms '' , states Thomas Purkarthofer , Ph.D. , Head of Business Development of VTU Technology .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Research Corporation Technologies Team

9 Team Members

Research Corporation Technologies has 9 team members, including current Chief Financial Officer, Senior Vice President, Christopher Martin.

Name

Work History

Title

Status

Christopher Martin

Chief Financial Officer, Senior Vice President

Current

Christopher Martin

Senior Vice President

Current

Avi J Roop

Managing Director

Current

Brad Morie

Senior Director

Current

Debra A Peattie

President

Former

Name

Christopher Martin

Christopher Martin

Avi J Roop

Brad Morie

Debra A Peattie

Work History

Title

Chief Financial Officer, Senior Vice President

Senior Vice President

Managing Director

Senior Director

President

Status

Current

Current

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.